Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis.

Background: Evidence on cost-effectiveness is important to make well-informed decisions regarding care delivery.

Aims: To determine the balance between costs and health outcomes of cognitive-behavioural therapy (CBT) compared with treatment as usual (TAU) in people with schizophrenia who have persistent and recurrent symptoms of psychosis.

Trial Number: ISRCTN57292778.